ACADIA Pharmaceuticals Inc. Aktie News

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 35,607 shares of common stock and 29,571 restricted stock units (“RSUs”) to seventeen new employees under Acadia's 2024 Inducement P...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or Phase 3 study readouts dur...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 187,664 shares of common stock and 89,582 restricted stock units (“RSUs”) to forty one new employees under Acadia's 2024 Inducement ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET. The event will feature members of Acadia's management team and R&D organization, key opinion leaders (KOL) and members of the caregiver community. To register for the live ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 4:00 p.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording w...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia's commercial leadership team with a focus on maximizing the potential of DAYBUE® and preparing for future product launches as the Company expands its rare disease portfo...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 7, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 64,252 shares of common stock and 56,277 restricted stock units (“RSUs”) to twenty-eight new employees under Acadia's 2024 Inducement...